Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/349893
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets |
Autor: | Bourgonje, Arno R.; Kloska, Damian; Grochot-Przeczek, Anna; Feelisch, Martin; Cuadrado, Antonio CSIC ORCID; Goor, Harry van | Palabras clave: | Inflammatory bowel disease Redox medicine Oxidative stress HIF-1α NRF2 |
Fecha de publicación: | abr-2023 | Editor: | Elsevier | Citación: | Redox Biology 60: 102603 (2023) | Resumen: | Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are intimately associated with inflammation and overproduction of reactive oxygen species (ROS). Temporal and inter-individual variabilities in disease activity and response to therapy pose significant challenges to diagnosis and patient care. Discovery and validation of truly integrative biomarkers would benefit from embracing redox metabolomics approaches with prioritization of central regulatory hubs. We here make a case for applying a personalized redox medicine approach that aims to selectively inhibit pathological overproduction and/or altered expression of specific enzymatic sources of ROS without compromising physiological function. To this end, improved ‘clinical-omics integration’ may help to better understand which particular redox signaling pathways are disrupted in what patient. Pharmacological interventions capable of activating endogenous antioxidant defense systems may represent viable therapeutic options to restore local/systemic redox status, with HIF-1α and NRF2 holding particular promise in this context. Achieving the implementation of clinically meaningful mechanism-based biomarkers requires development of easy-to-use, robust and cost-effective tools for secure diagnosis and monitoring of treatment efficacy. Ultimately, matching redox-directed pharmacological interventions to individual patient phenotypes using predictive biomarkers may offer new opportunities to break the therapeutic ceiling in IBD. | Versión del editor: | https://doi.org/10.1016/j.redox.2023.102603 | URI: | http://hdl.handle.net/10261/349893 | DOI: | 10.1016/j.redox.2023.102603 | E-ISSN: | 2213-2317 |
Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Personalized-redox-medicine_Bourgonje_Art_2023.pdf | 3,54 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
27
checked on 22-abr-2024
Page view(s)
15
checked on 27-abr-2024
Download(s)
8
checked on 27-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons